Company
Emulate Bio
The future of drug development is human.
Also known as Emulate
- Status
- Operatingas of 2026-09-23
- Business model
- B2B
- Legal name
- Emulate, Inc.
- emulatebio.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 8 October 2026
About
At Emulate, we understand that animal studies and reductionist models are limited because they are not based on integrated human biology.
Funding snapshot
- Total raised
- $264MSum of rounds, as of 2026-10-08Source (opens in a new tab)
- Latest round
- Series D+, $82M2021-09
Funding rounds
- Series D+
- $82M2021-09, Announced
- Round, 2021
- $57.5M2021-08-23, SEC form D sold, 7 investors
- Round, 2020
- $19.3M2020-03-06, SEC form D sold, 9 investors
- Round, 2019
- $28M2019-08-01, SEC form D sold, 8 investors
- Round, 2018
- $36M2018-06-06, SEC form D sold, 41 investors
- Round, 2017
- $746K2017-10-26, SEC form D sold, 4 investors
- Series B
- $28.8M2016-03-14, SEC form D sold, 10 investors
- Round, 2014
- $12M2014-07-11, SEC form D sold, 4 investors
Products
- Hardware
- Organ-Chip
Loading relationship preview